Nuvation BioNUVB
NUVB
About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Employees: 203
0
Funds holding %
of 6,790 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
59% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 37
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
25% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 5 (+1) [Q3]
5% more funds holding
Funds holding: 147 [Q2] → 154 (+7) [Q3]
4% less capital invested
Capital invested by funds: $448M [Q2] → $430M (-$18.5M) [Q3]
5.88% less ownership
Funds ownership: 62.13% [Q2] → 56.24% (-5.88%) [Q3]
97% less call options, than puts
Call options by funds: $7K | Put options by funds: $226K
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
81%
upside
Avg. target
$5.75
108%
upside
High target
$7
153%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Gregory Renza 49% 1-year accuracy 34 / 69 met price target | 117%upside $6 | Outperform Maintained | 7 Nov 2024 |
Wedbush David Nierengarten 43% 1-year accuracy 23 / 53 met price target | 81%upside $5 | Outperform Reiterated | 22 Oct 2024 |
HC Wainwright & Co. Robert Burns 43% 1-year accuracy 60 / 139 met price target | 153%upside $7 | Buy Maintained | 16 Sept 2024 |
Wedbush David Nierengarten 43% 1-year accuracy 23 / 53 met price target | 81%upside $5 | Outperform Reiterated | 11 Sept 2024 |
Financial journalist opinion
Based on 4 articles about NUVB published over the past 30 days
Neutral
Business Wire
1 week ago
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 9:10 a.m. ET. A live webcast of the fireside chat will be available on the.
Neutral
Business Wire
3 weeks ago
Nuvation Bio to Present at the Jefferies London Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Jefferies London Healthcare Conference in London, U.K., on Tuesday, November 19, 2024, at 3:30 a.m. ET/8:30 a.m. GMT. A live webcast of the presentation will be available on the Nuvation Bio website at htt.
Negative
Benzinga
3 weeks ago
Top 4 Health Care Stocks That May Plunge This Quarter
As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Neutral
Business Wire
4 weeks ago
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, reflected on the quarter and stated: “In the third quarter, we continued to execute on our goal of bringing taletrectinib to people l.
Neutral
Business Wire
1 month ago
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw.
Neutral
Business Wire
2 months ago
Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
Neutral
Business Wire
2 months ago
Nuvation Bio to Present at the Cantor Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 2024, at 9:45 a.m. E.T. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.
Positive
Seeking Alpha
3 months ago
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption.
Neutral
Business Wire
4 months ago
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “In the second quarter, we were pleased to share data at ASCO from TRUST-I, the pivotal study of taletrectinib in China, which although immature due to an early data cutoff, demonstrated taletrectinib's efficacy, durabil.
Neutral
Business Wire
4 months ago
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced multiple updates for its taletrectinib program. Data from the global, pivotal Phase 2 TRUST-II study has been accepted for an oral presentation at WCLC 2024 taking place September 7-10 in San Diego, California. Pooled data from both pivotal Phase 2 studies, TRUST-I and TRUST-II, has been accepted for a poster pr.
Charts implemented using Lightweight Charts™